Polycystic Kidney Disease Treatment Drugs Market 2027 By Drug Class, Distribution Channel, and Geography | The Insight Partners

Polycystic Kidney Disease Treatment Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Vasopressin Receptor Antagonists (Vaptans), Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Ii Receptor Antagonists, Calcium Channel Blockers (CCB), Antibiotics Phosphate Binders); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Report Code: TIPRE00016902 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Polycystic (polly-SIS-tick) kidney disease (PKD) is a type of genetic disease. It causes cyst growth (extracellular bodies) inside the kidney and may lead to chronic kidney diseases, further resulting in kidney failure or end-stage renal disease (ESRD). Therefore, various companies have designed treatment for polycystic kidney diseases; however, it may vary from person to person.

MARKET DYNAMICS

The polycystic kidney disease treatment drugs market growth is anticipated to grow due to increasing chronic kidney diseases, growing generic pharmaceutical industry, and growing number of startups. The growing investment by the government for the development of pharmaceutical sector is expected to serve vital growth opportunities for the market growth.

MARKET SCOPE

The "Polycystic Kidney Disease Treatment Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of polycystic kidney disease treatment drugs market with detailed market segmentation by drug class and distribution channel. The polycystic kidney disease treatment drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in polycystic kidney disease treatment drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The polycystic kidney disease treatment drugs market is segmented on the basis of drug class and distribution channel. Based on drug class, the market is divided into vasopressin receptor antagonists (Vaptans), angiotensin-converting enzyme (ACE) inhibitors, angiotensin Ii receptor antagonists, calcium channel blockers (CCB), and antibiotics phosphate binders. And based on distribution channel, the market is classified as hospital pharmacies, retail pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the polycystic kidney disease treatment drugs market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The polycystic kidney disease treatment drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting polycystic kidney disease treatment drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the polycystic kidney disease treatment drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the polycystic kidney disease treatment drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from polycystic kidney disease treatment Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for polycystic kidney disease treatment drugs in the global market. Below mentioned is the list of few companies engaged in the polycystic kidney disease treatment drugs market.

The report also includes the profiles of key players in polycystic kidney disease treatment drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Merck and Co., Inc.
  •  Par Pharmaceutical Companies, Inc.
  •  Silvergate Pharmaceuticals Inc.
  •  Valeant Pharmaceuticals, Inc.
  •  Teva Pharmaceutical Industries Ltd
  •  Mylan Pharmaceuticals Inc.
  •  AstraZeneca
  •  Novartis AG
  •  Boehringer Ingelheim
  •  GlaxoSmithKline plc

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Polycystic Kidney Disease Treatment Drugs Market - By Drug Class
1.3.2 Polycystic Kidney Disease Treatment Drugs Market - By Distribution Channel
1.3.3 Polycystic Kidney Disease Treatment Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 Europe - Pest Analysis
4.2.2 Asia-Pacific - Pest Analysis
4.2.3 Middle East and Africa - Pest Analysis
4.2.4 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS - GLOBAL MARKET OVERVIEW
6.2. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. VASOPRESSIN RECEPTOR ANTAGONISTS (VAPTANS)
7.3.1. Overview
7.3.2. Vasopressin Receptor Antagonists (Vaptans) Market Forecast and Analysis
7.4. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
7.4.1. Overview
7.4.2. Angiotensin-Converting Enzyme (ACE) Inhibitors Market Forecast and Analysis
7.5. ANGIOTENSIN II RECEPTOR ANTAGONISTS
7.5.1. Overview
7.5.2. Angiotensin Ii Receptor Antagonists Market Forecast and Analysis
7.6. CALCIUM CHANNEL BLOCKERS (CCB)
7.6.1. Overview
7.6.2. Calcium Channel Blockers (CCB) Market Forecast and Analysis
7.7. ANTIBIOTICS PHOSPHATE BINDERS
7.7.1. Overview
7.7.2. Antibiotics Phosphate Binders Market Forecast and Analysis
8. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1 Europe Polycystic Kidney Disease Treatment Drugs Market Overview
9.1.2 Europe Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis
9.1.3 Europe Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 Europe Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 Europe Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 Germany Polycystic Kidney Disease Treatment Drugs Market
9.1.5.1.1 Germany Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.1.2 Germany Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.1.5.2 France Polycystic Kidney Disease Treatment Drugs Market
9.1.5.2.1 France Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.2.2 France Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.1.5.3 Italy Polycystic Kidney Disease Treatment Drugs Market
9.1.5.3.1 Italy Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.3.2 Italy Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.1.5.4 Spain Polycystic Kidney Disease Treatment Drugs Market
9.1.5.4.1 Spain Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.4.2 Spain Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.1.5.5 United Kingdom Polycystic Kidney Disease Treatment Drugs Market
9.1.5.5.1 United Kingdom Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.5.2 United Kingdom Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.1.5.6 Rest of Europe Polycystic Kidney Disease Treatment Drugs Market
9.1.5.6.1 Rest of Europe Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.1.5.6.2 Rest of Europe Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2. ASIA-PACIFIC
9.2.1 Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market Overview
9.2.2 Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis
9.2.3 Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Australia Polycystic Kidney Disease Treatment Drugs Market
9.2.5.1.1 Australia Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.1.2 Australia Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2.5.2 China Polycystic Kidney Disease Treatment Drugs Market
9.2.5.2.1 China Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.2.2 China Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2.5.3 India Polycystic Kidney Disease Treatment Drugs Market
9.2.5.3.1 India Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.3.2 India Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2.5.4 Japan Polycystic Kidney Disease Treatment Drugs Market
9.2.5.4.1 Japan Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.4.2 Japan Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2.5.5 South Korea Polycystic Kidney Disease Treatment Drugs Market
9.2.5.5.1 South Korea Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.5.2 South Korea Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.2.5.6 Rest of Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market
9.2.5.6.1 Rest of Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.2.5.6.2 Rest of Asia-Pacific Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.3. MIDDLE EAST AND AFRICA
9.3.1 Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market Overview
9.3.2 Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis
9.3.3 Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 South Africa Polycystic Kidney Disease Treatment Drugs Market
9.3.5.1.1 South Africa Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.3.5.1.2 South Africa Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.3.5.2 Saudi Arabia Polycystic Kidney Disease Treatment Drugs Market
9.3.5.2.1 Saudi Arabia Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.3.5.2.2 Saudi Arabia Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.3.5.3 U.A.E Polycystic Kidney Disease Treatment Drugs Market
9.3.5.3.1 U.A.E Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.3.5.3.2 U.A.E Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.3.5.4 Rest of Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market
9.3.5.4.1 Rest of Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.3.5.4.2 Rest of Middle East and Africa Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.4. SOUTH AND CENTRAL AMERICA
9.4.1 South and Central America Polycystic Kidney Disease Treatment Drugs Market Overview
9.4.2 South and Central America Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis
9.4.3 South and Central America Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 South and Central America Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 South and Central America Polycystic Kidney Disease Treatment Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 Brazil Polycystic Kidney Disease Treatment Drugs Market
9.4.5.1.1 Brazil Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.4.5.1.2 Brazil Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.4.5.2 Argentina Polycystic Kidney Disease Treatment Drugs Market
9.4.5.2.1 Argentina Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.4.5.2.2 Argentina Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
9.4.5.3 Rest of South and Central America Polycystic Kidney Disease Treatment Drugs Market
9.4.5.3.1 Rest of South and Central America Polycystic Kidney Disease Treatment Drugs Market by Drug Class
9.4.5.3.2 Rest of South and Central America Polycystic Kidney Disease Treatment Drugs Market by Distribution Channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. POLYCYSTIC KIDNEY DISEASE TREATMENT DRUGS MARKET, KEY COMPANY PROFILES
12.1. MERCK AND CO., INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PAR PHARMACEUTICAL COMPANIES, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. SILVERGATE PHARMACEUTICALS INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. VALEANT PHARMACEUTICALS, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN PHARMACEUTICALS INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ASTRAZENECA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVARTIS AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BOEHRINGER INGELHEIM
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. GLAXOSMITHKLINE PLC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Merck and Co., Inc.
2. Par Pharmaceutical Companies, Inc.
3. Silvergate Pharmaceuticals Inc.
4. Valeant Pharmaceuticals, Inc.
5. Teva Pharmaceutical Industries Ltd
6. Mylan Pharmaceuticals Inc.
7. AstraZeneca
8. Novartis AG
9. Boehringer Ingelheim
10. GlaxoSmithKline plc
TIPRE00016902
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking